Summit Therapeutics Inc (SMMT)
$4.815
+0.17
(+3.55%)▲
Live
Insights on Summit Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 235.0K → -235.0K (in $), with an average decrease of 200.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -14.71M → -43.47M (in $), with an average decrease of 45.1% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 225.6% return, outperforming this stock by 240.0%
Performance
- $4.61$5.07$4.82
4.46%
Downside
Day's Volatility :9.17%
Upside
4.93%
- $1.50$5.39$4.82
68.88%
Downside
52 Weeks Volatility :72.17%
Upside
10.58%
Returns
| Period | Summit Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 3.56% | 0.5% | 0.0% |
6 Months | 152.72% | 13.1% | 0.0% |
1 Year | 154.1% | 8.6% | 1.6% |
3 Years | -14.36% | 16.9% | -18.5% |
Highlights
Market Capitalization | 3.4B |
Book Value | $0.06 |
Earnings Per Share (EPS) | 0.38 |
PE Ratio | 12.58 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -33.27% |
Return On Equity TTM | -130.59% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 705.0K |
EBITDA | -114.8M |
Diluted Eps TTM | 0.38 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.06 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 34.99%
Technicals Summary
Sell
Neutral
Buy
Summit Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Summit Therapeutics Inc | 27.22% | 152.72% | 154.1% | -14.36% | 35.17% |
 Moderna, Inc. | 12.95% | 67.08% | -9.94% | -21.73% | 380.19% |
 Regeneron Pharmaceuticals, Inc. | 8.37% | 22.23% | 29.67% | 88.29% | 219.12% |
 Novo Nordisk A/s | 3.65% | 27.43% | 51.59% | 225.57% | 442.2% |
 Vertex Pharmaceuticals Incorporated | 6.4% | 11.58% | 21.26% | 97.24% | 156.84% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Summit Therapeutics Inc | 12.58 | 12.58 | 0.0 | 0.0 | -1.31 | -0.33 | NA | 0.06 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.67 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.57 | 28.57 | 1.46 | 44.24 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.83 | 44.83 | 2.4 | 3.4 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 27.17 | 27.17 | 0.53 | 16.94 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Summit Therapeutics Inc | Sell | $3.4B | 35.17% | 12.58 | 0.0% |
Moderna, Inc. | Buy | $47.0B | 380.19% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $106.7B | 219.12% | 28.57 | 29.45% |
Novo Nordisk A/s | Buy | $573.2B | 442.2% | 44.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $108.1B | 156.84% | 27.17 | 39.46% |
Institutional Holdings
BlackRock Inc
1.39%Vanguard Group Inc
1.00%Geode Capital Management, LLC
0.44%State Street Corporation
0.35%Northern Trust Corp
0.16%Charles Schwab Investment Management Inc
0.14%
Company Information
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Organization | Summit Therapeutics Inc |
Employees | 105 |
CEO | Mr. Robert W. Duggan |
Industry | Health Technology |
